His unique combination of medical and biomedical engineering expertise enables him to assist our clients in effectively developing and refining new device solutions for patients. He will also provide invaluable guidance in helping them obtain marketing approvals for successful commercialization.
Phoenix, AZ (PRWEB) September 22, 2009
Medelis, Inc., a full-service oncology contract research organization (CRO) in the US and Europe, today announced that the company is expanding its services to support medical devices under the guidance of Inder Makin, M.D., Ph.D., who joins the company as Vice President, Devices & Radiological Health.
Dr. Makin has more than 20 years of experience developing "concept to clinic" healthcare technologies in both academia and industry. He has developed medical ultrasound-based research programs at various institutes, taking concepts (including catheter-based devices for intravascular thrombolysis, transdermal drug delivery devices and non-invasive and intracorporeal tissue ablation devices) through feasibility and launch.
"We are extremely pleased to add Dr. Makin to our team of experts," said Medelis President & CEO Bob Bosserman. "His unique combination of medical and biomedical engineering expertise enables him to assist our clients in effectively developing and refining new device solutions for patients. He will also provide invaluable guidance in helping them obtain marketing approvals for successful commercialization."
Medelis will support medical device manufacturers throughout the product life cycle including early design and prototyping, simulation, preclinical and phase I-III clinical studies. The company will also collaborate with clients to help them gain regulatory and marketing approvals.
About Inder Makin, M.D., Ph.D.
During the past 20 years, Dr. Inder Makin has been active in strategy development and implementation of medical device technology from lab to market. He is a co-founder of Guided Therapy Systems, LLC (VP Applications and Clinical Development), Ulthera, Inc. and Xthetix, Inc. (VP Clinical and Application Development). Scientifically, he has been involved in the basic and applied research of ultrasound-tissue interaction, sound-bubble interaction and propagation of high-intensity ultrasound through tissue-like media. He has published more than 20 scientific papers, chaired various national and international conferences, and holds 8 patents. He received his M.D. from Jiwaji University, India in 1985, Diplom Ingenieur in Biomedical Engineering from Fachhochschule Hamburg, Germany, and his Ph.D. in Biomedical Engineering from Univ. of Texas at Austin, with specialization in nonlinear and medical acoustics. He is also an accredited medical sonographer (RDMS).
Medelis, Inc. is an oncology contract research organization providing a total solution for biotechnology and pharmaceutical companies seeking rapid drug development and approval. Medelis' medical founders, team physicians and clinical trial management physicians, including Dan Von Hoff, James Gourzis and Michael Gordon, are internationally-recognized oncology thought and opinion leaders who understand the future of personalized medicine and threshold of credibility trials. Medelis also supports medical device manufacturers from early design through regulatory approval.
Medelis is privately-held with US locations in Phoenix (headquarters), Nashville, Boston and Reno. The company's European CRO services are headquartered in Port Vendres, France.
# # #